Literature DB >> 20371133

Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy.

Kornelia Szluha Lazanyi1, Andrij Abramyuk, Gunter Wolf, Sergey Tokalov, Klaus Zöphel, Steffen Appold, Thomas Herrmann, Michael Baumann, Nasreddin Abolmaali.   

Abstract

OBJECTIVE: The goal of this study was to investigate the local tumor blood supply parameters relative tumor blood volume (rTBV) and transfer coefficient (K(trans)) measurable with dynamic contrast enhanced computed tomography (DCE-CT) in patients with non-small-cell lung cancer (NSCLC) scheduled for radiation therapy (RT).
MATERIALS AND METHODS: rTBV and K(trans) were measured before RT in 31 patients with clinically inoperable NSCLC (Stages I-III), which received (n=19) or did not receive (n=12) induction chemotherapy (IChT). Possible links between rTBV and K(trans) and time-to-progression (TTP), overall survival (OS) and maximum standardized uptake value (SUV(max)) from fluorodeoxyglucose positron emission tomography as well as histology were analyzed.
RESULTS: NSCLC showed a wide range of rTBV and K(trans) values as estimated by DCE-CT (6.4±0.6ml/100ml and 18.2±1.5ml/100ml/min correspondingly). A significant difference in rTBV values in patients with IChT (4.6±0.6ml/100ml) and without IChT (7.5±0.9ml/100ml; p=0.023), depending on the number of cycles of the IChT and the clinical stage was found. A negative correlation between rTBV and TTP was revealed only in RT patients up-staged by FDG-PET/CT from stage III to stage IV (n=7, r=-0.96, p=0.0006). An inverse correlation between K(trans) and TTP (n=24, r=-0.53, p=0.008) was observed in all RT patients. No relevant correlation was detected between rTBV, K(trans) and SUV(max) or histologic subtypes and grading.
CONCLUSIONS: Tumor blood supply parameters derived from DCE-CT are useful to characterize tumor vascularization before radiotherapy in patients with NSCLC and data on outcome prediction are supplemented.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20371133     DOI: 10.1016/j.lungcan.2010.03.004

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

Review 1.  Imaging of lung cancer in the era of molecular medicine.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  Acad Radiol       Date:  2011-01-28       Impact factor: 3.173

Review 2.  Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Marco Das; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

3.  An empirical mathematical model applied to quantitative evaluation of thioacetamide-induced acute liver injury in rats by use of dynamic contrast-enhanced computed tomography.

Authors:  Kenya Murase; Shuichiro Kobayashi; Akihiro Kitamura; Taro Matsushita; Shigeyoshi Saito; Motoko Nishiura
Journal:  Radiol Phys Technol       Date:  2012-09-19

4.  Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours.

Authors:  A Abramyuk; V Hietschold; S Appold; R von Kummer; N Abolmaali
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

5.  Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer.

Authors:  P Veit-Haibach; D De Ruysscher; W van Elmpt; M Das; Martin Hüllner; H Sharifi; K Zegers; B Reymen; P Lambin; J E Wildberger; E G C Troost
Journal:  Radiother Oncol       Date:  2013-09-14       Impact factor: 6.280

6.  Are complex DCE-MRI models supported by clinical data?

Authors:  Chong Duan; Jesper F Kallehauge; G Larry Bretthorst; Kari Tanderup; Joseph J H Ackerman; Joel R Garbow
Journal:  Magn Reson Med       Date:  2016-03-04       Impact factor: 4.668

Review 7.  The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Authors:  Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-30       Impact factor: 7.038

Review 8.  Visualization, imaging and new preclinical diagnostics in radiation oncology.

Authors:  Clemens C Cyran; Philipp M Paprottka; Michel Eisenblätter; Dirk A Clevert; Carsten Rist; Konstantin Nikolaou; Kirsten Lauber; Frederik Wenz; Daniel Hausmann; Maximilian F Reiser; Claus Belka; Maximilian Niyazi
Journal:  Radiat Oncol       Date:  2014-01-03       Impact factor: 3.481

9.  Correlation of intra-tumor 18F-FDG uptake heterogeneity indices with perfusion CT derived parameters in colorectal cancer.

Authors:  Florent Tixier; Ashley M Groves; Vicky Goh; Mathieu Hatt; Pierre Ingrand; Catherine Cheze Le Rest; Dimitris Visvikis
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.